LABFF (Laboratorios Farmaceuticos Rovi) 1-Year Sharpe Ratio: -87.40 (As of Jul. 11, 2026)


LABFF Laboratorios Farmaceuticos Rovi SA LABFF
93 GF Score
Price $90.61
GF Value $82.42
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi 1-Year Sharpe Ratio?

Laboratorios Farmaceuticos Rovi LABFF 93 1-Year Sharpe Ratio is -87.40 as of Jul. 11, 2026. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-11), Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio is -87.40.

Laboratorios Farmaceuticos Rovi  (OTCPK:LABFF) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Laboratorios Farmaceuticos Rovi 1-Year Sharpe Ratio Related Terms

LABFF vs ZTS, UTHR, VTRS: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio falls into.


LABFF
93GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -87.40 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a 1-Year Sharpe Ratio of -87.40 as of Jul. 11, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio too high?
Laboratorios Farmaceuticos Rovi's current 1-Year Sharpe Ratio is -87.40. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's 1-Year Sharpe Ratio of -87.40 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current 1-Year Sharpe Ratio is -87.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current 1-Year Sharpe Ratio of -87.40. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current 1-Year Sharpe Ratio is -87.40. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current 1-Year Sharpe Ratio is -87.40 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.

Key valuation signals for LABFF:

  • 1-Year Sharpe Ratio: -87.40
  • GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for LABFF

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.61
Price
$82.42
GF Value